Literature DB >> 12648897

Which neuroleptic would psychiatrists take for themselves or their relatives?

Tilman Steinert1.   

Abstract

OBJECTIVE: Psychiatrists should be asked which neuroleptic they would prefer for themselves and their relatives in the case of first manifestation of schizophrenia.
METHOD: Questionnaires were answered by 66 psychiatrists from 13 different sites in Baden-Wuerttemberg (South West Germany). Only those were included who had treated more than 50 patients with schizophrenia within the last 5 years (n = 54).
RESULTS: The psychiatrists were experienced with conventional and most of the atypical agents. Fifty-one point nine percent would take olanzapine as first line treatment, 20.4% risperidone, 13.0% quetiapine, 9.3% amisulpride, 3.7% haloperidol and 1.9% perazine. In four cases, different substances were preferred for oneself and relatives.
CONCLUSION: Most psychiatrists would not take conventional neuroleptics, though 70% of prescriptions for schizophrenic patients have been conventional neuroleptics in Germany in 2000. The preferences among atypicals correspond well with the current prescription practice in Germany.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648897     DOI: 10.1016/s0924-9338(02)00004-4

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  2 in total

1.  "Doctor, what would you do?": physicians' responses to patient inquiries about periviable delivery.

Authors:  Brownsyne Tucker Edmonds; Fatima McKenzie; Janet E Panoch; Lucia D Wocial; Amber E Barnato; Richard M Frankel
Journal:  Patient Educ Couns       Date:  2014-09-30

2.  Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?

Authors:  Sameer Jauhar; Sinan Guloksuz; Olivier Andlauer; Greg Lydall; João Gama Marques; Luis Mendonca; Iolanda Dumitrescu; Costin Roventa; Nele De Vriendt; Jeroen Van Zanten; Florian Riese; Izu Nwachukwu; Alexander Nawka; Raphael Psaras; Neil Masson; Rajeev Krishnadas; Umberto Volpe
Journal:  BMC Psychiatry       Date:  2012-03-30       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.